GLP-1

Authoritative sources

• Wikidata (Q414309)
• MeSH (D052216)
• Wikipedia

Evidence base

• Randomized Controlled Trial · 2022 · Landmark

  Tirzepatide Once Weekly for the Treatment of Obesity

  New England Journal of Medicine · Jastreboff AM, Aronne LJ, Ahmad NN, et al. (SURMOUNT-1)

  The pivotal trial that established tirzepatide (Zepbound / Mounjaro) as the most effective medication studied for weight loss to date.

• Randomized Controlled Trial · 2021 · Landmark

  Once-Weekly Semaglutide in Adults with Overweight or Obesity

  New England Journal of Medicine · Wilding JPH, Batterham RL, Calanna S, et al. (STEP 1)

  The pivotal trial that established semaglutide (Wegovy) as a highly effective medication for weight loss in adults without diabetes.

• Randomized Controlled Trial · 2025

  Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

  The New England journal of medicine · Wharton S, Aronne LJ, Stefanski A, Alfaris NF, et al.

• Meta-Analysis · 2025

  Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials

  Diabetes care · Wong HJ, Sim B, Teo YH, Teo YN, et al.

• Randomized Controlled Trial · 2025

  Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

  The New England journal of medicine · Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, et al.

• Systematic Review · 2025

  Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis

  Metabolism: clinical and experimental · Karakasis P, Patoulias D, Fragakis N, Mantzoros CS

• Systematic Review · 2024

  Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

  BMJ (Clinical research ed.) · Yao H, Zhang A, Li D, Wu Y, et al.

• Randomized Controlled Trial · 2021

  Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

  Lancet (London, England) · Rosenstock J, Wysham C, Frías JP, Kaneko S, et al.

• Randomized Controlled Trial · 2021

  Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

  Lancet (London, England) · Davies M, Færch L, Jeppesen OK, Pakseresht A, et al.

• Randomized Controlled Trial · 2021

  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

  The New England journal of medicine · Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, et al.

• Systematic Review · 2021

  Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

  BMJ (Clinical research ed.) · Palmer SC, Tendal B, Mustafa RA, Vandvik PO, et al.

Where GLP-1 appears on Kindr Health